Summary of exercised warrants by Board members and senior executives in NXTCL
Stem cell company NextCell Pharma AB ("NXTCL") announces today, that members of the Board Anders Essen-Möller, Edvard Smith, Hans-Peter Ekre, Niclas Löwgren, CEO Mathias Svahn and CFO Leo Groenewegen have exercised all of their respective series TO 1 warrants. In total this means that 173 430 warrants are to be converted, corresponding to a total investment of SEK 867 150. In total, investments from the Board and Management correspond to approximately 6 percent of the total outstanding warrants.
Below, each person’s amount of to be exercised series TO 1 warrants is presented:
- Mathias Svahn, CEO NXTCL, 39 200 warrants
- Leo Groenewegen, CFO NXTCL, 5 050 warrants.
- Anders Essen-Möller, Chairman of the Board of NXTCL, 96 000 warrants.
- Edvard Smith, Board member NXTCL, 3 060 warrants.
- Hans-Peter Ekre, Board member NXTCL, 6 120 warrants
- Niclas Löwgren, Board member NXTCL, 24 000 warrants.
Previously, the largest shareholder Diamyd Medical AB ("Diamyd") announced that it will exercise its 296 800 warrants, which corresponds to approximately 10 percent of the outstanding warrants. Shareholder and partner Polski Bank Komorek Macierzystych S.A. ("PBKM") has earlier entered a subscription commitment to exercise all of the 320 000 warrants they hold, which corresponds to approximately 11 percent of the outstanding warrants. In total, utilization by the Board, Management, Diamyd and PBKM will correspond to approximately 27 percent of the outstanding warrants.
Financial adviser and issuing agent
Sedermera Fondkommission is the financial advisor and issuing agent to NXTCL for the subscription period of the series TO 1 warrants.
For more information regarding the subscription of series TO 1 warrants, please contact:
Sedermera Fondkommission
Phone: 040-615 14 10
E-mail: info@sedermera.se
Stay up to date with the latest development in NextCell Pharma
LinkedIn: https://www.linkedin.com/company/15255207/
Twitter: https://twitter.com/NextCellPharma
For more information about NextCell Pharma AB, please contact:
Mathias Svahn, CEO
Leo Groenewegen, CFO
Phone: 08-735 5595
E-mail: info@nextcellpharma.com
About NextCell Pharma AB:
Stem cells are expected to change the way how many of today's life-threatening diseases are treated. NextCell Pharma AB develops ProTrans, a drug candidate consisting of stem cells for the primary treatment of autoimmune and inflammatory diseases as well as for use in kidney transplants. ProTrans consists of selected stem cells derived from the umbilical cord tissue with NextCell Pharma AB's proprietary method. In addition, the company has a service called Cellaviva, Sweden's first and only IVO-approved stem cell bank for the family-saving of stem cells from umbilical cord blood and umbilical cord tissue.